Watch Belite Bio Inc ADR for free: we tell you when fair value or trend changes.

Belite Bio Inc (BLTE) stock: price, quality, comparison

Price, quality, revenue and earnings and the peer comparison for Belite Bio Inc, from audited financials.

Price: $154.19. No valuation: the company's figures do not support a reliable fair value right now, so we deliberately show none.

Revenue growth (quarter YoY) 0.0% (industry 0.0%)

Growth analysisrevenue history, year by year Quality 31/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ADR

Thin data Nov 6, 2026

Belite Bio Inc

BLTE · US

Mixed vs. peers (3/6)

Quality 31/100

Negative free cash flow

Narrow moat 9/100

Thin data

No fair value

Watch Belite Bio Inc ADR for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Which stocks are undervalued right now? Check free Discover now →

Company profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States.

Show moreShow less

Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.

The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout.

Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Quality Score breakdown

Overall quality 31/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0

How much profit the company makes from its sales and capital

Quality Growth 75

Are margins and returns getting better?

Cashflow 0

Do the profits arrive as real cash?

Financial strength 100

Debt, balance sheet and risk of trouble

Investment 0

Does it invest with discipline instead of growing at any price?

Low Volatility 57

How calm the share price moves, does not count

Price momentum 50

Price momentum of the last 3 to 12 months, does not count

Near the 52-week high 65

Distance to the 52-week high, does not count

New shares 0

Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

Watch BLTE, get fair value alerts →

Compare Belite Bio Inc ADR with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 559 stocks

Beats the industry median on 3/5 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 31 · Bottom 25%

Profitability

Return on assets −9.9% · Above median

Operating margin (12 months) 0.0% · Above median

Growth and dividend

Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 8.04× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value	Compare
Incyte Corporation INCY	$119.65	$199.23	+67%	vs BLTE
Regeneron Pharmaceuticals, Inc REGN	$904.35	$1,275	+41%	vs BLTE
Genmab A/S GMAB	kr 3,527	kr 3,999	+13%	vs BLTE
WuXi Biologics (Cayman) Inc 2269	HK$47.62	HK$53.55	+12%	vs BLTE
Samsung Biologics Co 207940	1,516,000 KRW	1,667,600 KRW	+10%	vs BLTE
Vertex Pharmaceuticals Incorporated VRTX	$547.09	$596.75	+9%	vs BLTE
argenx SE ARGX	$927.21	$908.40	−2%	vs BLTE
CSL Limited CSL	A$202.04	A$183.04	−9%	vs BLTE
Celltrion, Inc 068270	211,000 KRW	74,945 KRW	−64%	vs BLTE
Royalty Pharma plc RPRX	$67.30	$19.01	−72%	vs BLTE

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks Undervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more

Run the numbers yourself: free valuation calculators

DCF Calculator P/E Ratio Calculator PEG Ratio Calculator Graham Number Peter Lynch Formula DDM Calculator Intrinsic Value Intrinsic vs Extrinsic Value P/E Ratio by Sector

Frequently asked questions

What is the quality score of BLTE?

Belite Bio Inc has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

How solid is the balance sheet of Belite Bio Inc (BLTE)?

Balance-sheet figures for Belite Bio Inc (as of Nov 6, 2026): return on equity −22.1%. They feed the Quality Score of 31/100, which measures business quality independently of the share price.

Which stocks are comparable to Belite Bio Inc ADR?

From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

What is the share price of Belite Bio Inc (BLTE)?

The closing price on Nov 6, 2026 was $154.19. We carry closing prices from our data provider, not a live tick.

Key figures of Belite Bio Inc

How large is the market capitalisation of Belite Bio Inc (BLTE)?

The market capitalisation of Belite Bio Inc is $6.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What are the earnings per share of Belite Bio Inc (BLTE)?

Earnings per share at Belite Bio Inc are $−2.74. Earnings per share over the last twelve months: total profit spread across every single share.

What is the return on equity of Belite Bio Inc (BLTE)?

The return on equity (ROE) of Belite Bio Inc is −22.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Belite Bio Inc (BLTE)?

On an EBIT basis the return on assets of Belite Bio Inc is −30.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

How much free cash flow does Belite Bio Inc (BLTE) generate?

The free cash flow of Belite Bio Inc is −$37.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net cash does Belite Bio Inc (BLTE) hold?

Belite Bio Inc holds more cash than debt, $353M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Belite Bio Inc ADR in the live analysis

One click puts Belite Bio Inc ADR on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.